pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Vyvanse
drug
save

Vyvanse

Marketedupdated 3mo ago
by $TAK TAKEDA PHARMACEUTICAL CO LTD
Approved
annual revenue · 2024–2024peak $1.5B
2024: $1.5B2024$1.5B
community read0 votes

all catalysts(0)

nothing on the calendar yet

Trials studying Vyvanse

  • phase1A Study to Evaluate the Abuse Potential of EB-1020 Immediate-Release in Healthy Recreational Stimulant Userscompletedn=80
  • phase1A Trial to Assess How Centanafadine Interacts With Stimulants in the Bodyrecruitingn=42
  • phase2Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorderrecruitingn=105
  • phase4Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Chronic Fatigue Syndromecompletedn=26
  • phase1To Compare and Evaluate the Oral Bioavailability of Lisdexamfetamine 70 mg Capsule With That of Elvanse® 70 mg Capsules, Hard Lisdexamfetamine Dimesylate in Healthy, Adult, Human Subjects Under Fasting Conditions.completedn=48
  • —A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetaminecompletedn=430,000
  • phase4Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autismcompletedn=48

News(0)

no news has mentioned this drug yet

brand
Vyvanse
generic
lisdexamfetamine
indication
ADHD, binge eating disorder
phase
marketed
approved
2007-02-23
Data sources
openFDA · ClinicalTrials.gov
last refreshed 15m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?